開拓藥業-B(09939.HK):盧燕已獲委任為執行董事
格隆匯2月3日丨開拓藥業-B(09939.HK)董事會宣佈,自2022年1月31日起:盧燕已獲委任為執行董事;及陸剛已辭任非執行董事。
公吿顯示,盧燕,39歲,於2019年12月獲委任為集團首席財務官及2021年11月獲委任為公司聯席公司祕書,主要負責集團的財務內控、投資者關係、公共關係和資金業務。加入集團前,盧女士擁有超過13年的投資銀行業務經驗。於2018年7月,盧女士加入廣發融資(香港)有限公司,離任時擔任董事、投資銀行業務主管及董事總經理。於2007年9月至2018年7月,盧女士於UBS Securities Hong Kong Limited任職,離任時為亞洲醫療健康集團(Asian healthcare group)執行董事,並自2014年起一直擔任香港首次公開發售(IPO)的簽字保薦人。盧女士為北京大學光華管理學院金融學碩士,中國人民大學金融學學士。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.